 | This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (June 2023) (Learn how and when to remove this message) |
 | |
| Company type | Joint venture |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 2009; 16 years ago (2009) |
| Headquarters | London, England, UK |
| Area served | Worldwide |
| Key people | Deborah Waterhouse (CEO) |
| Products | Pharmaceuticals |
| Owners | |
| Number of employees | c. 1,100 (2023) |
| Website | viivhealthcare |
ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS. Its global headquarters is located in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company. In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi. According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.
ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.
ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.
Products
The company markets 17 products:
- Nucleoside reverse transcriptase inhibitors (NRTIs):
- abacavir (brand name Ziagen)
- lamivudine (brand names Epivir and 3TC)
- zidovudine (brand name Retrovir and AZT)
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
- delavirdine (brand name Rescriptor, no longer available)
- Attachment inhibitors
- fostemsavir (brand name Rukobia)
- Integrase strand transfer inhibitors (INSTIs):
- dolutegravir (brand name Tivicay)
- cabotegravir (brand names Apretude ; and Vocabria/Cabenuva )
- Protease inhibitors:
- fosamprenavir (brand names Lexiva and Telzir)
- nelfinavir (brand name Viracept)
- Entry inhibitors:
- maraviroc (brand names Selzentry and Celsentri)
- Antiretroviral fixed-dose combinations, including several single-pill regimens:
- abacavir/lamivudine (brand names Epzicom and Kivexa)
- abacavir/lamivudine/zidovudine (brand name Trizivir)
- lamivudine/zidovudine (brand name Combivir)
- abacavir/dolutegravir/lamivudine (brand name Triumeq)
- dolutegravir/lamivudine (brand name Dovato)
- dolutegravir/rilpivirine (brand name Juluca – in partnership with Janssen Pharmaceuticals)
Treatment access programs
ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa.
The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.
In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.
See also
References
- ^ Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required)
- "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.
- "ViiV vows joint venture will help fight HIV". Financial Times. London. Retrieved 3 November 2023.
- "ViiV Healthcare Company Website. About Us – Locations" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010
- "Our HIV medicines". Retrieved 10 March 2022.
- "Generic Rescriptor Availability". Drugs.com. Retrieved 10 March 2022.
- ^ "ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014
- Reuters "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies" Africa – the Good News. 19 July 2010
- "ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV". Olean Times Herald. Retrieved 3 March 2020.
| GSK | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subsidiaries |
| ||||||||
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
